What if the key to a thriving surgical practice isn’t working harder? Tune in for tips on efficiency in our latest episode of The Next Breast Thing. @SBoolbol

In this episode of The Next Breast Thing, we navigate the emotional, ethical, and clinical complexities of breast reconstruction. Who decides and what it truly means to feel whole again? @SBoolbol

Cabbage leaves, antibiotics, & breast milk ice cream? 🤯 The Next Breast Thing Podcast busts lactation myths with experts Dr. Katrina Mitchell and Dr. Helen Johnson. @SBoolbol

Will #breastsurgery be needed in the future? Tune in as we explore the evolving role of breast surgeons in neoadjuvant treatment—plus caves, quakes, and a pregnant cow! 🔗 @SBoolbol

Discover how the Histolog Scanner is transforming breast-conserving surgery. Join us May 8 at 11 AM ET for an exploration into intraoperative margin assessment (IOMA) and SHIELD study data. @samantree @pathologynews #breastsurgery.

Breast surgeons will remain the central role in the treatment of breast cancer care. ⁦@DrJudyBoughey⁩ #asbrs2025

The importance of mentorship ⁦@DrJudyBoughey⁩ #asbrs2025

Lessons learned in doing clinical trials ⁦@DrJudyBoughey⁩ #asbrs2025

The @asbrs Presidential address. ⁦@DrJudyBoughey⁩ #asbrs2025

The life and times of our @asbrs President ⁦@DrJudyBoughey⁩ #asbrs2025

Dr. Berry introducing Dr. Boughey (BOH-eee). ⁦@DrJudyBoughey⁩ #asbrs2025

HER-2 ultra low and HER-2 low subtypes can be treated with Enhertu in the metastatic setting. #asbrs2025

Selected patients with minimal residual axillary disease after neoadjuvant chemotherapy do not need ALND. #asbrs2025

Z11 criteria can be applied to all histologic subtypes. #asbrs2025

Results from INSEMA trial. #asbrs2025

COMET trial data. #asbrs2025

ICE3 5-year data. #asbrs2025

For BRCA+ patients, risk reducing mastectomy should not be mandated.#asbrs2025

Complex sclerosing lesions do not need routine excision. Only 1% upgrade rate. #asbrs2025

3D mammograms detect interval cancers better than standard digital mammogram #asbrs2025